


Kyle David Fink, Ph.D.

Research/Academic Interests	Dr. Fink's lab has a primary interest in developing novel biological interventions and treatments for genetically-linked neurodevelopmental and neurodegenerative disorders. The Fink lab using stem cell and animal models of neurological diseases to assess treatment efficacy. The lab specializes in gene modification using CRISPR/dCas9 and gene therapy using AAV.
Title	Associate Director, Gene Therapy Center Assistant Professor, Department of Neurology
Specialty	Gene Modification, Stem Cell Biology, Genetics, Genomics, Neurodevelopmental Disorders, Neurodegenerative Conditions
Department	Neurology
Division	Neurology
Center/Program Affiliation	Stem Cell Research Program UC Davis MIND Institute
Address/Phone	UC Davis Institute for Regenerative Cures (IRC), 2921 Stockton Blvd. Sacramento, CA 95817 Phone: 916-703-9300
Additional Phone	Clinic Phone: 916-703-9300 Clinic Phone: 916-703-9368 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	Ph.D., Neurosciene, Central Michigan University, Mount Pleasant MI 2013 Ph.D., Neuroimmunology, University of Nantes, Nantes, France 2013 B.S., Psychology, University of Portland, Portland OR 2008
Fellowships	Stem Cell Postdoctoral Scholar, UC Davis, Sacramento CA 2013-2017
Professional Memberships	American Society for Cell and Gene Therapy Society for Neuroscience
Honors and Awards	CDKL5 Forum, Award for Excellence, Lab of the Year 2022, 2022 Excellence in Research Award, WeHaveAFace.org, 2018 Hot Topics in Neuroscience, Society for Neuroscience, 2017 Hope Award, WeHaveAFace.org, 2017 Founder's Award, Michigan Chapter Society for Neuroscience, 2013
Select Recent Publications	https://pubmed.ncbi.nlm.nih.gov/?term=kyle%20d%20fink



Kyle David Fink, Ph.D.


Deng P, Halmai JANM, Beitnere U, Cameron D, Martinez ML, Lee CC, Waldo JJ, Thongphanh K, Adhikari A, Copping N, Petkova SP, Lee RD, Lock S, Palomares M, O'Geen H, Carter J, Gonzalez CE, Buchanan FKB, Anderson JD, Fierro FA, Nolta JA, Tarantal AF, Silverman JL, Segal DJ, Fink KD. An in vivo Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models. *Front Mol Neurosci.* 2022 Jan 27;14:789913. doi:10.3389/fnmol.2021.789913. PMID:35153670.

Halmai JANM, Deng P, Gonzalez CE, Coggins NB, Cameron D, Carter JL, Buchanan FKB, Waldo JJ, Lock SR, Anderson JD, O'Geen H, Segal DJ, Nolta J, Fink KD. Artificial escape from XCI by DNA methylation editing of the CDKL5 gene. *Nucleic Acids Res.* 2020 Mar 18;48(5):2372-2387. doi:10.1093/nar/gkz1214. PMID:31925439.

O'Geen H, Bates SL, Carter SS, Nisson KA, Halmai J, Fink KD, Rhie SK, Farnham PJ, Segal DJ. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. *Epigenetics Chromatin.* 2019 May 3;12(1):26. doi:10.1186/s13072-019-0275-8. PMID:31053162.

Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Tempkin T, Wheelock V, Nolta JA. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. *Mol Ther.* 2016 May;24(5):965-77. doi:10.1038/mt.2016.12. Epub 2016 Jan 14. PMID:26765769.

Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. *Cell Transplant.* 2016;25(4):677-86. doi:10.3727/096368916X690863. Epub 2016 Feb 4. PMID:26850319.



Kyle David Fink, Ph.D.

Rossignol J, Fink KD, Crane AT, Davis KK, Bombard MC, Clerc S, Bavar AM, Lowrance SA, Song C, Witte S, Lescaudron L, Dunbar GL. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number. *Stem Cell Res Ther.* 2015 Feb 19;6(1):9. doi:10.1186/scri545. PMID:25971780.

Fink KD, Crane AT, Lévêque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE, Antcliff A, Starski PA, Lu M, Lescaudron L, Rossignol J, Dunbar GL. Intra-striatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. *Stem Cells Transl Med.* 2014 May;3(5):620-31. doi:10.5966/sctm.2013-0151. Epub 2014 Mar 21. PMID:24657963.

Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, Lowrance S, Bombard M, Dekorver N, Lescaudron L, Dunbar GL. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. *Stem Cells.* 2014 Feb;32(2):500-9. doi:10.1002/stem.1508. PMID:23939879.

Fink KD, Rossignol J, Lu M, Lévêque X, Hulse TD, Crane AT, Nerriere-Daguin V, Wyse RD, Starski PA, Schloop MT, Dues DJ, Witte SJ, Song C, Vallier L, Nguyen TH, Naveilhan P, Anegon I, Lescaudron L, Dunbar GL. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. *Cell Transplant.* 2014;23(11):1407-23. doi:10.3727/096368913X670958. Epub 2013 Jul 22. PMID:23879897.

Fink KD, Rossignol J, Crane AT, Davis KK, Bombard MC, Bavar AM, Clerc S, Lowrance SA, Song C, Lescaudron L, Dunbar GL. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis. *Stem Cell Res Ther.* 2013 Oct 24;4(5):130. doi:10.1186/scri341. PMID:24456799.

© 2024 UC Regents